Background:  The purpose of PARAGON is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular (CV) death and HF hospitalizations in patients with HF with preserved EF (HFpEF) Trial Registration No: NCT02625922 (clinicaltrials.gov) Link  Trial Status: Randomized worldwide: 4600, Recruitment stopped Randomized in Basel: 7 Enrolling Centers:  Switzerland Worldwide: Basel, Zürich, Bern, Lausanne,   39 in different countries  Biel, Lugano Core Study Team: 
Home News Team Current Studies Publications Events Cooperations Contact
© Christian Mueller, 2012 - 2017  │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: June 2017
Beate Hartmann Ph.D. Dr. Samyut Shrestha Christian Puelacher Kristin Podkowik